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We conducted a feasibility study to examine whether small numbers of cancer cells could be utilised for analysis of the EGFR gene
status using the loop-hybrid mobility shift assay, which is a modified heteroduplex technique. Cytology specimens obtained by
transbronchial abrasion were successfully used for analysis of the EGFR gene status in 50 of 52 (96.2%) patients diagnosed with class
V non-small-cell carcinoma. Furthermore, the relationship between the EGFR gene status and clinical outcome was analysed in 25
patients treated with gefitinib. Overall, 10 of 11 patients with EGFR mutations in exon 19 or 21 showed tumour regression with
gefitinib treatment, compared to only two of 14 patients with wild-type EGFR. The response rate was significantly higher in the EGFR
mutation group than in the wild-type EGFR group (90.9 vs 14.3%, P¼0.00014). Logistic regression analysis revealed that EGFR
mutations in cytology specimens represented an independent predictor of the gefitinib response. The overall and progression-free
survivals were significantly longer in the EGFR mutation group than in the wild-type EGFR group (Po0.05). In conclusion, cytology
specimens could be useful for analysing the EGFR status in the majority of patients with non-small-cell lung cancer to determine
whether they are likely to benefit from gefitinib treatment.
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Non-small-cell lung cancer (NSCLC) is the leading cause of cancer
deaths in Japan. Current chemotherapy regimens for metastatic
NSCLC are not particularly effective, and the disease cannot be
cured even with the most effective platinum and new combination
chemotherapies. Recent progress in lung cancer biology has led to
the development of small-molecule inhibitors of target proteins
involved in proliferation, apoptosis and angiogenesis. The
epidermal growth factor receptor (EGFR) superfamily was
identified early on as a potential therapeutic target in solid
tumours. Given the biological importance of the EGFR molecular
network in carcinomas, several molecules that can inhibit the
EGFR tyrosine kinase domain have been synthesised. These
inhibitors include gefitinib and erlotinib, both of which are orally
active and can produce an objective response in previously treated
or untreated advanced NSCLC (Fukuoka et al, 2003; Kris et al,
2003; Miller et al, 2004; Perez-Soler et al, 2004). A previous
randomised study demonstrated that addition of gefitinib to
standard platinum-based chemotherapy did not improve the
outcome of patients with NSCLC (Giaccone et al, 2004; Herbst
et al, 2004). Furthermore, consolidation with gefitinib did not
improve the outcome in NSCLC patients receiving full-dose
chemotherapy and thoracic radiotherapy followed by docetaxel
(Kelly et al, 2005). A placebo-controlled study also failed to
demonstrate that gefitinib improved survival (Thatcher et al,
2005). On the basis of these results, the use of gefitinib has not
been recommended for treatment of patients with NSCLC in
Europe and the United States.
Meanwhile, responders to chemotherapy generally have a better
prognosis than non-responders, and chemosensitivity is an
important factor in deciding which patients should receive
chemotherapy. Responsiveness to gefitinib is a characteristic of
distinct subgroups of patients, such as women, patients who have
never smoked, patients with adenocarcinoma and Asians (Kris
et al, 2003; Miller et al, 2004; Thatcher et al, 2005). Although the
level of EGFR protein expression is not associated with the
gefitinib response, specific missense and deletion mutations in
the tyrosine kinase domain of the EGFR gene have been reported
to be associated with gefitinib sensitivity (Lynch et al, 2004;
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sPaez et al, 2004). A retrospective study demonstrated that NSCLC
patients with EGFR mutations have a better outcome with gefitinib
treatment than patients with the wild-type EGFR gene (Mitsudomi
et al, 2005). The National Cancer Institute of Canada Clinical
Trial Group BR.21 placebo-controlled study demonstrated a
survival advantage for patients with NSCLC who received erlotinib
after other treatments had failed (Shepherd et al, 2005). That study
also evaluated the EGFR gene status and analysed its relationship
with the clinical outcome. It was concluded that the presence of
an EGFR mutation is not indicative of a survival benefit, but may
increase the responsiveness of patients with NSCLC to erlotinib
treatment (Tsao et al, 2005). Therefore, it seems important to limit
gefitinib or erlotinib treatment to NSCLC patients with EGFR
mutations.
Although tumour tissue, such as that obtained by surgical
resection or transbronchial biopsy, has usually been used for
analysis of EGFR mutations in lung cancer, a small number of
patients with NSCLC can be diagnosed purely on the basis of
cytology using small numbers of cancer cells. In a previous large-
scale study examining the benefits of erlotinib treatment for
NSCLC, analysis of EGFR mutations using cytology specimens was
possible in only 197 of 731 (27%) patients (Tsao et al, 2005). In
addition, in a study that demonstrated a 30% objective response to
gefitinib as a first-line treatment for NSCLC, the EGFR gene status
could be examined using cytology specimens in only 13 of 40
(32.5%) patients (Niho et al, 2006). These low numbers may reflect
the difficulties associated with obtaining biopsy specimens by
bronchoscopic examination for the diagnosis of NSCLC. Thus, in
order to apply the EGFR mutation strategy to all patients, a new
method that requires only a small number of cells is necessary. A
novel method for the detection of small deletions as well as point
mutations in DNA fragments based on retarded migration of loop
hybrid (LH) DNA has recently been developed (Matsukuma et al,
2006). The LH DNA is formed by hybridisation of a single-
stranded DNA fragment to a complementary strand with the
deletion of seven nucleotides. In comparison with the normal
duplex DNA, the LH DNA shows strikingly retarded electro-
phoretic migration in a native polyacrylamide gel owing to the
presence of a single-stranded nucleotide loop situated in the
middle of the duplex. The nucleotide sequence of the loop affects
the mobility of the LH DNA to such an extent that displacement of
the loop position by a single nucleotide is distinguishable. These
anomalous electrophoretic properties of LH DNA have been
adapted for the detection of hotspot point mutations of the EGFR
gene in lung adenocarcinoma. The new mutation detection system,
known as the LH-mobility shift assay (LH-MSA), is very sensitive
and may be useful for molecular diagnosis of clinical cancer
specimens. Thus, in order to develop a method for analysing the
EGFR gene status in large numbers of patients and applying the
results to decide whether gefitinib treatment is indicated, we
performed a feasibility study to clarify whether the LH-MSA using
small numbers of cancer cells could be applied for analysis of
EGFR mutations, and then further evaluated its prediction ability
of the EGFR gene mutation status relative to the gefitinib response.
PATIENTS AND METHODS
This study was approved by the Institutional Review Board of
Kanagawa Cancer Center.
Patients
A total of 52 patients with cytologically proven class V NSCLC were
entered into the present study. Written informed consent for EGFR
genetic analysis of the tumour tissue or cancer cells was obtained
from each patient. Some patients received gefitinib 250mg/day at
Kanagawa Cancer Center.
Samples
Cytology specimens obtained by transbronchial abrasion were
used for the analysis of EGFR gene mutations. All EGFR analyses
were blinded with respect to the clinical response and demo-
graphic information before interpretation of the combined data.
Isolation of DNA from specimens for cytologic diagnosis
Glass slides with cells that had been prepared for cytologic
diagnosis by Papanicolaou staining were dipped in xylene until the
coverslips naturally peeled off, and the slides were then rehydrated
through a series of ethanol dilutions and air-dried. A Pinpoint
Slide DNA Isolation System (Zymo Research, Orange, CA, USA)
was used to extract DNA from the cells in accordance with the
manufacturer’s instructions. Briefly, an appropriate amount of a
viscous solution (Pinpoint Solution, supplied in the kit) was
applied over the area of cancer cells on the slide and air-dried to a
thin film, together with the underlying cells. The film was then
lifted with a blade, transferred to a tube containing a solution of
proteinase K and digested at 551C for 4h. The tube was further
incubated at 981C for 10min to inactivate the enzyme and then
immediately quenched on ice. After vigorous vortexing, the tube
was centrifuged and part of the supernatant was directly subjected
to the following polymerase chain reaction (PCR)-based analyses.
Mutation analyses by LH-MSA
The LH-MSA, a modified heteroduplex technique, was used to
analyse the EGFR gene mutations. Briefly, two genomic DNA
fragments spanning the mutation hotspots in exons 19 and 21 were
amplified by PCR with the primers e19F and e19R (for exon 19) or
e21F and e21R (for exon 21) (Table 1). At the end of the PCR
amplification cycle, a specific LH probe for the detection of exon
19 mutations (e19LH) or exon 21 mutations (e21LH) was added to
the PCR reaction solution at 500nM. The mixture was then
subjected to an LH cycle consisting of denaturation at 941C for
2min, annealing of the LH probe at 551C for 15s and extension of
the LH probe by PCR at 681C for 4min. After the LH cycle, the
product was separated by electrophoresis in a preformed native
10% polyacrylamide gel (Atto Inc., Tokyo, Japan) in Tris-glycine
buffer (37.5mM Tris, 288mM glycine). Next, the gels were stained
with SYBR Green I (Cambrex Bio Science, Rockland, ME, USA)
and the DNA fragments were detected with a laser scanning imager
(STORM860; Amersham Biosciences, Piscataway, NJ, USA). The
bands representing LH DNAs were then excised and crushed in a
small quantity of water, before an aliquot of each extract was
re-amplified by PCR. The PCR products were subcloned into the
pCR4TOPO (Invitrogen, Carlsbad, CA, USA) plasmid vector, and
the nucleotide sequences were confirmed. All PCR amplifications
and elongation reactions with LH probes were performed with
Table 1 PCR primers and LH-G probes for LH-MSA
e19F ggactctggatcccagaaggtg
e19R catttaggatgtggagatgagc
e21F ggcatgaactacttggaggac
e21R cttactttgcctccttctgcatg
e19LP ggactctggatcccagaaggtgagaaagttaaaattcccgtcgctatcaaggaa
ttaagagagcaacatctccgaaagccaacaaggaaatcctcgat
e21LP cttactttgcctccttctgcatggtattctttctcttccgcacccagcag*******
agcccaaaatctgtgatcttgacatgctgcg
or simply
cttactttgcctccttctgcatggtattctttctcttccgcacccagcagagcccaaaa
tctgtgatcttgacatgctgcg
LH-MSA¼loop-hybrid mobility shift assay; PCR¼polymerase chain reaction.
*Deleted nucleotides from the normal sequence. The mutational hot spot is
underlined.
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hybridisation-enhancing reagent (Invitrogen).
Statistical analysis
The w
2 test was used to identify differences in the gefitinib
responses between wild-type and mutant EGFR genes. The
influence of each factor on the response to gefitinib was examined
by logistic regression analysis. The Kaplan–Meier method was
used to estimate the probability of survival, and differences in
survival were analysed by the log-rank and Wilcoxon tests.
Differences at Po0.05 were considered significant. All analyses
were performed using StatView or Fisher’s software.
RESULTS
A feasibility study was carried out to determine whether cytology
specimens obtained by transbronchial abrasion were applicable for
analysis of the EGFR gene status. A total of 52 patients who were
diagnosed cytologically as having class V NSCLC by transbronchial
abrasion were entered into this study. A Pinpoint Slide DNA
Isolation System was used to extract DNA from cancer cells alone
on glass slides (Figure 1), and the EGFR gene status was analysed
using LH-MSA as described in the Patients and methods. Analysis
of the EGFR gene status using a few cancer cells was not possible in
just two patients (3.8%), owing to insufficient amounts of the
recovered DNA, but was possible in the remaining 50 patients
(96.2%). Representative EGFR gene statuses of cytology specimens
are shown in Figure 2. Deletion mutations in exon 19 were
identified as bands showing delayed mobility owing to hetero-
duplex formation (Figure 2A), whereas point mutations in exon
21 were observed as extra bands (Figure 2B). (Table 2)
Among the 50 patients, 25 patients with metastatic lesions
received 250mg/day gefitinib treatment at Kanagawa Cancer
Center (Table 3). Among them, 22 patients had been treated with
one or two regimens of chemotherapy before starting gefitinib, but
none received any further chemotherapy after the gefitinib
treatment. Overall, eight of these patients were male and 17 were
female, and they included 11 smokers and 14 non-smokers.
Regarding the cancer types, 22 patients had adenocarcinoma, one
had squamous cell carcinoma, one had non-small-cell carcinoma
and one had undifferentiated carcinoma. We further divided the
patients into an EGFR mutation group (n¼11) and a wild-type
EGFR group (n¼14), and compared their EGFR statuses and
clinical outcomes. Among the 11 patients with EGFR mutations, 10
showed tumour regression after gefitinib treatment and one
showed no cancer progression over 1 year. Only two of 14 patients
with the wild-type EGFR gene showed gefitinib-induced tumour
regression. The response rate of patients with EGFR mutations was
significantly higher than that of patients with the wild-type EGFR
gene (90.9 vs 14.3%, P¼0.00014, w
2 test). Logistic regression
analysis revealed that EGFR mutations were the only significant
factor contributing to gefitinib sensitivity (P¼0.0016; Table 4).
Patients with EGFR mutations showed significantly longer
progression-free survival than patients with the wild-type EGFR
gene (P¼0.037, log-rank test; P¼0.018, Wilcoxon test; Figure 3).
Patients with EGFR mutations also showed marginally, but
significantly, longer overall survival than patients with the wild-
type EGFR gene (P¼0.076, log-rank test; P¼0.046, Wilcoxon
test; Figure 4).
DISCUSSION
We analysed cytological specimens from a total of 52 patients with
class V NSCLC and were able to identify the EGFR gene status in 50
patients (96.2%). This is a very high percentage compared with
previous studies in which the EGFR gene status was clarified in
about 30% of patients using biopsy or resected tumour specimens
(Tsao et al, 2005; Niho et al, 2006). Furthermore, the EGFR gene
status identified using LH-MSA in the present study was well
correlated with the antitumour effect of gefitinib. Responsiveness
to gefitinib has been demonstrated in distinct subgroups of
patients, such as women, patients who have never smoked, patients
with adenocarcinoma and Asians (Kris et al, 2003; Miller et al,
2004; Thatcher et al, 2005). We carried out logistic regression
analysis of various factors, and found that only EGFR mutations in
cytology specimens represented an independent predictor for
sensitivity to gefitinib. Taken together, these findings indicate that
AB
C
Figure 1 Removal of cytology specimens for analysis of the EGFR gene
status. Glass slides previously prepared for cytologic diagnosis with
Papanicolaou staining were dipped in xylene until the coverslips naturally
peeled off, and the samples were then rehydrated for recovery of the
cancer cells. (A–C) An area of cancer cells before (A) and after (C)
removal by the PinPoint method is shown. In (B), the obtained cancer cells
in the boxed area of (A) are shown at a higher magnification.
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Figure 2 Detection of EGFR gene mutations from cytology specimens
by LH-MSA. (A) Analysis of deletion-mutations in exon 19. Mutated
products are identified as bands showing delayed mobility owing to
heteroduplex formation in LH-MSA. The locations of the shifted bands are
indicated by the vertical bar on the right. (B) Analysis of point mutations in
exon 21. Mutated cases are indicated by arrowheads above the panels. A
vertical arrow at the left side of (A) shows the area where LH bands
appear. bp: base pairs, M: molecular size marker, LH: loop hybrid.
Table 2 Type of in-frame deletion mutations in exon 19
G1 del(9) del(L747-E749),A750P
G2 del(15) del(E746-A750), c2481G4A
G3 del(15) del(E746-A750)
G4 del(15) del(R748-T751),L747S
G5 del(18) del(L747-S752),E746V
G6 del(18) del(L747-S752)
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majority of patients using LH-MSA, thereby making it possible to
decide which patients would benefit from gefitinib treatment.
Clinical experience has demonstrated that a patient with poor
performance owing to respiratory failure caused by lymphangitis
carcinomatosa responded to gefitinib treatment and showed an
improved status with relief of dyspnoea (Patient No. 9 in Table 3).
In general, such patients have invariably shown no response to
anticancer drugs and experienced severe toxicities, thus contra-
indicating them for chemotherapy. Therefore, it would be clinically
beneficial to examine the sensitivity of such patients to gefitinib
before treatment.
Gefitinib is not currently a first-line anticancer drug, and is
usually used after previous treatments with several conventional
chemotherapeutic reagents. It is probable that the preceding
chemotherapy may modify the sensitivity to gefitinib, as acquired
cross-resistance of cancer cells to multiple anticancer drugs is a
commonly encountered clinical phenomenon. Therefore, we
Table 3 Patient characteristics, EGFR gene status and clinical outcome
Diagnosis Pretreatment Gefitinib treatment
EGFR
Patient Gender Smoke
Age
(years) PS Stage Cytology Exon 19 Exon 21 1st 2nd 3rd Age PS Effect Ongoing
Progression-
free survival
after gefitinib
(days)
Overall
survival after
gefitinib
(days) Alive
1 M Smoker 57 1 IV non-sm del(15)G4 W NP+CPT+TRT DP+TXT — 58 1 PR + 219 219 +
2 F Non 63 1 IV ad del(15)G3 F856L DP+Gem — — 66 1 PR + 1214 1214 +
3 F Non 43 2 IV ad del(18) G5 W Tx+CPT — — 46 2 PR   876 878  
4 F Non 61 3 IV ad del(15)G3 W Tx+CPT — — 64 1 PR   486 528  
5 F Smoker 60 1 IV ad W L858R Tx+CPT — — 61 1 PR + 295 295 +
6 F Non 56 0 IIA ad del(15) G2,G4 L858A/L858W surgery WBI — 59 1 NC   367 537 +
7 F Non 62 1 IIIB ad del(15) G4 W Tx+CPT — — 64 1 PR + 629 629 +
8 F Non 55 1 IV ad del(18) G5 W Tx+CPT — — 56 1 PR + 516 516 +
9 F Non 58 2 IV ad del(15) G3 W Tx+CPT — — 60 4 PR + 482 482 +
10 F Non 47 1 IV ad W L858A/L858R Tx+CPT — — 50 1 PR + 395 429 +
11 F Non 60 0 IIIA ad del(15)G2 nd surgery NP+CPT — 64 1 PR + 817 817 +
12 F Smoker 52 1 IIIA sq W W NP+CPT DP+TXT — 54 1 NC   138 141  
13 M Smoker 69 3 IV udca W W — — — 70 3 NC   107 274  
14 M Smoker 69 2 IV ad W W Tx+CPT — — 70 1 NC + 436 436 +
15 F Non 66 1 IV ad W W Tx+CPT — — 68 1 PR + 308 308 +
16 M Smoker 66 0 IIIB ad W W surgery NP+CPT TXT 68 1 PD   21 326 +
17 M Smoker 61 1 IV ad W W Tx+CPT — — 62 1 PD   16 157  
18 F Non 65 1 IIIB ad W W Tx+CPT — — 67 1 NC + 476 476 +
19 M Smoker 70 1 IIIB ad W W NP+CPT — — 71 1 PR + 254 254 +
20 M Smoker 57 2 IV ad W W WBI DP+Gem — 59 1 NC   340 351  
21 F Non 69 1 IV ad W W Tx+CPT — — 71 1 NC + 689 689 +
22 M Smoker 41 1 IV ad W W DP+VNR TXT+Gem — 45 1 NC + 852 852 +
23 F Non 65 1 IIIA ad W W surgery DP+VNR — 72 1 PD   25 611 +
24 F Smoker 80 1 IV ad W W NP+CPT — — 81 2 PD   23 69  
25 F Non 69 2 IV ad W W WBI — — 70 3 NC + 338 338 +
ad¼adenocarcinoma; CPT¼irinotecan; DP¼cisplatin; EFGR¼epidermal growth factor receptor; F¼female; G2¼del(746E-750A); G3¼del(746E-750A); G4¼del(747L-
751T) P741T; G5¼del(747L-752S) E746V; Gem¼gemcitabine; M¼male; NC¼no change; nd¼not done; non-sm¼non-small-cell carcinoma; NP¼nedaplatin; PD,
progressive disease; PR¼partial response; PS¼performance status; sq¼squamous cell carcinoma; TRT¼thoracic radiotherapy; Tx¼paclitaxel; TXT¼docetaxel;
udca¼undifferentiated carcinoma; VNR¼vinorelbine; W¼wild type; WBI, whole-brain irradiation.
Table 4 Logistic regression analysis of various factors that predict
gefitinib effectiveness
Variable Odds ratio 95% CI P-value
Gender Female/male 0.233 0.036–1.513 0.127
Pathology Ad/non-ad 0.5 0.039–6.353 0.593
Smoking status Never/current 0.208 0.037–1.163 0.074
EGFR status Mutation/wild 0.017 0.001–0.212 0.002
ad¼adenocarcinoma; CI¼confidence interval; EGFR¼epidermal growth factor
receptor. Values in italics denote significance at Po0.05.
Progression-free survival
Mutation (median 486 days, n = 11)
Wild-type (median 281 days, n = 14)
(P = 0.037, log-rank test; P = 0.018, Wilcoxon's test)
1
0.8
0.6
0.4
0.2
0
0 200 400 600 800 1000 1200 1400
Time (days)
Figure 3 Progression-free survival curves according to the EGFR gene
status, constructed using the Kaplan–Meier method. Patients with EGFR
mutations have significantly longer progression-free survival than patients
with the wild-type EGFR gene.
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drugs, including gefitinib, just before their use. The LH-MSA used
in the present study requires only a small number of cancer cells,
which may be sampled using common clinical procedures, such as
collection of sputum, pleural effusion or peripheral blood. Our
present findings suggest that the majority of patients could be
tested in this manner for the presence of EGFR mutations, thus
allowing selection of patients who would be likely to benefit from
gefitinib treatment.
Our results confirmed that specific missense and deletion
mutations in the tyrosine kinase domain of the EGFR gene are
associated with the response to gefitinib. However, some of our
patients without EGFR mutations also responded to gefitinib,
suggesting that the clinical benefits of the drug cannot be
explained only by the presence of EGFR mutations. Previous
studies have demonstrated that the EGFR gene copy number is
significantly associated with the response to gefitinib, and that
gefitinib-treated patients showing EGFR gene amplification or high
polysomy have significantly better responses, a longer time to
progression and longer survival than patients with no or low EGFR
genomic gain (Cappuzzo et al, 2005; Takano et al, 2005). Another
study demonstrated an association between EGFR mutations and
increased EGFR gene copy numbers in the human lung cancer cell
line H3255 (Andrechek et al, 2000), although a large-scale study
found that the presence of mutations was not correlated with either
the expression or copy number of EGFR (Tsao et al, 2005).
Therefore, determination of not only mutations but also the
number of copies of EGFR is controversial for more certain
clarification of likely responders to gefitinib. We are now planning
a prospective study to examine whether the EGFR gene status
revealed by cytology specimens using LH-MSA is able to select
likely responders to gefitinib and long-term survivors.
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